ImageneBio (NASDAQ:IMA) Releases Earnings Results, Misses Estimates By $1.44 EPS

ImageneBio (NASDAQ:IMA) issued its quarterly earnings data on Wednesday. The company reported ($2.91) earnings per share for the quarter, missing the consensus estimate of ($1.47) by ($1.44), FiscalAI reports.

ImageneBio Trading Down 2.0%

IMA stock traded down $0.17 during trading on Friday, reaching $8.16. 34,606 shares of the stock were exchanged, compared to its average volume of 28,596. The firm’s 50 day moving average is $8.25 and its 200 day moving average is $12.71. The firm has a market cap of $32.68 million, a P/E ratio of -1.01 and a beta of 0.42. ImageneBio has a twelve month low of $7.24 and a twelve month high of $23.28.

Hedge Funds Weigh In On ImageneBio

A number of large investors have recently modified their holdings of IMA. XTX Topco Ltd raised its holdings in ImageneBio by 350.6% during the first quarter. XTX Topco Ltd now owns 56,452 shares of the company’s stock worth $72,000 after buying an additional 43,924 shares during the last quarter. Goldman Sachs Group Inc. raised its holdings in shares of ImageneBio by 62.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 76,464 shares of the company’s stock worth $98,000 after acquiring an additional 29,369 shares during the last quarter. Bridgeway Capital Management LLC bought a new position in ImageneBio in the 3rd quarter valued at about $104,000. Aldebaran Capital LLC bought a new position in ImageneBio in the 3rd quarter valued at about $159,000. Finally, Squarepoint Ops LLC acquired a new position in ImageneBio during the 3rd quarter valued at about $197,000. 75.00% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts have commented on the company. Wedbush reduced their price target on ImageneBio from $25.00 to $23.00 and set a “neutral” rating on the stock in a research report on Friday, July 25th. Leerink Partners started coverage on ImageneBio in a research note on Friday, October 24th. They issued an “outperform” rating and a $30.00 price objective on the stock. Zacks Research downgraded shares of ImageneBio from a “strong-buy” rating to a “hold” rating in a research report on Monday, September 29th. Weiss Ratings started coverage on shares of ImageneBio in a report on Wednesday, October 22nd. They set a “sell (e-)” rating for the company. Finally, Wall Street Zen raised ImageneBio to a “hold” rating in a research note on Friday, September 26th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, ImageneBio has an average rating of “Hold” and a consensus target price of $26.50.

ImageneBio Company Profile

ImageneBio, Inc, a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc and changed its name to ImageneBio, Inc in July 2025.